Tilray Ships CBD To US For Clinical Trials On Alcohol And PTSD

Tilray has begun shipping CBD to researchers at New York University to study alcohol and post-traumatic stress disorders, the Canadian pot company announced Thursday. It’s the second time it has received the U.S. Drug Enforcement Agency’s approval to send the compound to U.S. scientists.

The NYU researchers will test CBD in clinical trials aimed at treating alcohol use disorder and post-traumatic stress disorder.

The study could provide scientists with more clinical evidence on CBD. Consumers are raving that CBD treats everything from anxiety to pain, even though there’s not much data backing their claims up. Strict regulations have made it difficult for researchers to study cannabis.

Scientists are hopeful about CBD’s potential to treat alcohol use disorder and post-traumatic stress disorder. More than 15 million Americans are addicted to alcohol and more than 8 million experience PTSD, federal survey data shows. Both conditions can be debilitating and few medications treat them.